objective To compare the cost-utility of microscopic observation drug-susceptibility assay (MODS) and Xpert â MTB/RIF implementation for tuberculosis (TB) diagnosis in rural northern Mozambique.
Introduction
Tuberculosis (TB) is a leading cause of mortality worldwide. Together with HIV, it is the primary cause of death from an infectious disease. In 2014, there were an estimated 9.5 million new cases globally, and 1.5 million people died of TB. About 390 000 of those deaths were people living with HIV (PLWH) [1] .
Mozambique is considered by the WHO as a high TB/ high HIV burden country. TB incidence is 551 (IC95% 435-680)/100 000 population; representing 150 000 new cases every year (85 000 or 63% among HIV-infected patients) with approximately 45 000 annual deaths. The nationwide HIV prevalence is 12%, and 1.6 million are PLWH [2] . TB is the leading cause of death among PLWH [3] .
Sputum smear microscopy (SM) is the most common TB diagnostic test. However, it is not very sensitive, especially in HIV-infected patients in whom TB often has an atypical clinical presentation and a paucibacillary nature [4] . TB diagnostic delay in HIV-infected patients has been pointed out as one of the main factors for the high mortality of HIV/TB co-infection in high HIV prevalence settings [5, 6] . The global priorities for TB care and control are to improve case detection and to detect cases earlier, including cases of smear-negative disease, which are often associated with HIV co-infection and young age, and to enhance the capacity to diagnose multidrug-resistant tuberculosis (MDR-TB) [7, 8] .
Xpert â MTB/RIF (Cepheid, Sunnyvale, CA, USA) is a fully automated cartridge-based real-time DNA-based test that can detect both TB and resistance to rifampicin in less than 2 h. Xpert â MTB/RIF has been endorsed by WHO and recommended for expansion at a district level in low-income countries. It is recommended as the initial test in all adults and children presumed to have pulmonary MDR-TB or HIV-associated TB. It has also been recommended as the initial diagnostic test (rather than conventional microscopy and culture) in all children and adults suspected of having pulmonary TB although this recommendation remains conditional due to resource implications [8] . It is also considered the preferred initial diagnostic test for TB meningitis and a good replacement test for other forms of extra-pulmonary TB. According to a meta-analysis by the Cochrane Collaboration Group, overall sensitivity for Xpert â MTB/RIF is 88% (CI 82-92), decreasing to 76% (CI 63-85) in HIV-infected patients and to 61% (CI 40-81) in HIV+ smear-negative patients [9] Microscopic observation drug-susceptibility (MODS) assay is a cheap and low-complexity liquid culturebased technique for the diagnosis of TB infection and drug-susceptibility testing (DST). It has been evaluated under high-level laboratory conditions in African settings, namely in South Africa, Ethiopia, Zimbabwe and Uganda [13] [14] [15] [16] . WHO has endorsed the assay for DST but has not recommended its implementation at district level. However, it has been shown that technicians from peripheral health centre laboratories without previous experience in TB cultures can learn MODS technique in 3 weeks [17] . Published numbers for the cost per test for the MODS assay have varied, ranging from as little as 0.72 USD to 7.31 USD including labour costs, fixed costs and DST [18, 19] . A recent meta-analysis on MODS showed a global sensitivity of 96% (CI 94-98), with 88.3% (95% CI 86.18-90.2) in HIV-infected patients and 88.2% (95% CI 86.1-89.9) in HIV-infected with smear-negative TB [20, 21] . Therefore, its lower price per test could make it more cost-effective than Xpert â MTB/RIF. Another advantage is that it is patent-free. Challenges for the implementation of MODS are the need for more complex laboratory equipment (compromising a P2 biosafety cabinet, an inverted optic microscope, a centrifuge and an incubator), a stable electricity supply and 3 weeks of training. Cost-effectiveness evaluations for TB diagnostics are key to inform policymakers, as the main TB burden worldwide is supported by low-income countries where resources have to be allocated with extreme caution. So far, cost-effectiveness comparisons of Xpert â MTB/RIF and MODS have been limited to short-term evaluation on rather broad regional or country-level impact on TB transmission [22] . Our aim was to evaluate the long-term cost-utility of MODS -which is potentially less expensive and more effective -vs. that of Xpert â MTB/RIF for the diagnosis of TB in a rural health centre at a district level in a high HIV burden setting through a mathematical modelling approach.
Material and methods

Target population and setting
The target population was the population of Ancuabe district. Ancuabe is located in Northern Cabo Delgado province, one of the poorest provinces in Mozambique. Cabo Delgado has a population of 1.8 million inhabitants with 51.6% women; 80% of the population lives in rural areas, and the illiteracy rate is around 80% for women and 51% for men. Life expectancy is 54 years and less than 40% have access to health care [23, 24] . The prevalence of HIV is 9.4% [25] . HIV infection is responsible for at least 20% of the deaths in the province [26] .
Ancuabe measures 4606 km 2 and has a population of 118 926 inhabitants. The estimated HIV prevalence is about 5% [27] . In 2013, the district had two Type 1 health centres led by a physician with space for 87 inpatients (Ancuabe Sede and Metoro) and a basic laboratory. In these health centres, a chronic diseases unit/HIV Clinic offered HIV treatment and care. The district also had four Type 2 health centres that only had outpatient 
Diagnostic strategies evaluated
We analysed the use of three different techniques for the evaluation of TB suspects attending Ancuabe health centres: SM, MODS, and Xpert â MTB/RIF.
• SM was used as the base case scenario, as this was the standard of care in the district and it is the most common diagnostic tool for TB diagnosis worldwide. This strategy consisted of two SM examinations followed by a chest X-ray or antibiotic trial in smear-negative TB suspects.
• Xpert â MTB/RIF technique was evaluated in two ways: as a replacement of SM for initial evaluation or as an add-on test for smear-negative cases.
• MODS was also evaluated as a replacement of SM for initial evaluation or as an add-on test for smear-negative cases.
Development of a compartmental Markov TB Model
A stochastic, transmission, Markov TB Model was programmed in R to describe the transmission of TB and the interaction between the patients and the health system [28] . The model was stratified by age group and HIV status in analogy with previous models. Conventions adopted for previous epidemic models of major antituberculosis interventions and diagnostics were followed [29] [30] [31] [32] . The population was divided into different compartments according to TB disease status. The TB-infected population was further divided into different compartments through the diagnostic pathway as well as treatment states (Figure 1 ).Three methods were used to choose the model parameters: information available from a descriptive baseline study of the local TB programme outcomes [33] ; a systematic literature reviews with metaanalysis when deemed appropriate, and expert consultation when no other source was available [21] . The total population was maintained stable during the simulation by programming the birth rate equal to the death rate.
For calibration, parameters were given a probability distribution and the model was run 10 000 times. The goodness of fit to WHO 2000-2014 estimates for TB incidence was evaluated with the least squares method. Then, the sets of parameters were resampled with replacement 10 000 times with probability of sampling directly proportionate to the goodness of fit. This way, a 'best fit' set of parameters was obtained as well as a Figure 1 The structure of the compartmental Markov TB model. Dx, diagnosis; HC, health centre; LTFU, lost to follow-up; SN, smear negative; SP, smear positive; TB, tuberculosis.
posterior distribution for each parameter. The 'best fit' set of parameters was used for the cost-utility evaluation. The posterior distribution was used for the probabilistic sensitivity analysis (PSA).
Model assumptions were as follows: there is no multidrug resistant TB, HIV incidence stays at the 2014 level throughout the time of the study, patients are not started on TB treatment empirically (i.e. treatment based only on clinical symptoms, without any diagnostic test performed), and individuals show homogeneous mixing within the population.
Cost evaluation
A healthcare provider perspective was adopted for cost evaluation. A micro-costing approach was used. To estimate the capital costs and equipment costs, up-to-date Pro-forma invoices from local and international providers were used. The costs were annualised according to the half-life of the goods. The half-life was estimated by the WHO estimates (www.who.int/choice/costs/prices_t4/en/ index.html). As there were no tables available for Mozambique, Kenyan tables were used. In case, no source was found for the half-life, the most commonly used value of 5 years was used or different after expert consultation. To estimate the labour costs, the official salary tables for laboratory technicians of the Mozambican Ministry of Health were used. Data from previous publications or expert opinion were used to estimate costs if no better source was found. Costs were measured in 2013 USD. A 3% yearly discount rate was applied to both costs and effectiveness as recommended [34] . Costs were calculated with the model, depending on the population in each state at every time-point.
Health outcomes
Using the model, estimates of the number of TB patients, time of permanence in each state, life years lost due to disease and life years lived with disability were obtained. Disease-adjusted life years (DALYs) were calculated using the weights for TB of the Global burden of disease study 2010 [35] . For the calculation of life years lost, we used the standard expected years of life lost approach, establishing 82 years as the maximum life expectancy [34] . No age weighting was used. 
Cost-utility evaluation
For each run of the model, a total of 90 years (i.e. our time horizon) of TB transmission, diagnosis, and treatment was simulated. During the simulation, costs incurred and DALYs produced were calculated by the model and stored. For the cost-utility evaluation, the incremental costeffectiveness ratios (ICER) -that is the difference in costs divided by difference in health effects -compared with baseline strategy were calculated. These ICERs were calculated for each one of the different strategies evaluated.
A one-way sensitivity analysis was undertaken to evaluate the impact of the variation of different key parameters on the model output. It was performed for the following variables: TB prevalence, risk of infection sensitivity of the techniques for HIV-infected and not HIV-infected patients, and discount rate. A Monte-Carlo simulation was used for PSA, to evaluate the magnitude and impact of parameter uncertainty. The model was run 1000 times for each strategy. The willingness to pay threshold (WTP) was established at one time the per capita Gross National Income (GNI) of Mozambique in 2013 (590 USD) [36] . The CHEERS statement was followed for reporting [37] .
Results
Model
The compartmental TB model is presented in Figure 1 . A summary of the main parameters used for smear-positive (SP) TB is presented in Table 1 ; more details of the structure and parameters are described in Appendix S1. The code is available via e-mail to the corresponding author. A summary of costs is presented in Table 2 ; a more detailed description of the costs is available in Appendix S2.
Base case scenario results
Using SM as the only TB diagnostic technique, the model predicted a total burden of disease of 346 232.8 DALYs, and it cost a total of 758 687.5 USD.
MODS
MODS as an add-on study produced a decrease in DALYs of 2699.19 with an increase in the cost of 15 244 692 USD yielding an ICER of 5647.89 USD per DALY averted. MODS as a substitute for SM produced a decrease in DALYs of 2699.19 at an increase in the cost of 14 507 004 USD yielding an ICER of 5374.58 USD per DALY averted. Sensitivity analyses. In the one-way sensitivity analysis (Figure 2 ), MODS ICER was mainly affected by the prevalence of TB and the risk of infection, with the ICER inversely affected by the TB prevalence and risk of infection. TB diagnostic test sensitivity was not a big driver of ICER uncertainty.
The sensitivity analysis showed the same trend for both strategies, the add-on strategy and the substitution strategy, for all the evaluations. A post hoc sensitivity analysis was carried out to evaluate the effect of a possible reduction in the probability of completing the diagnostic pathway in the add-on strategy. A 10% reduction was Sensitivity analyses. Results of the one-way sensitivity analysis are shown in Figure 2 . The main factors impacting the ICER were, as for MODS, the risk of infection and TB prevalence. A post hoc sensitivity analysis was carried out to evaluate the effect of a possible reduction in the probability of completing the diagnostic pathway in the add-on strategy. A 10% reduction was applied, and the ICER did not rise significantly (346.08 USD/DALY averted). In the PSA (Figure 3 ), Xpert â MTB/RIF was fell within the WPT in 60.6% of the runs.
Discussion
Our results suggest that in this rural African setting substituting SM by Xpert â MTB/RIF would be the most cost-effective strategy compared to its implementation as an add-on strategy or MODS implementation. However, the degree of uncertainty is high.
The development of the Xpert â MTB/RIF assay was a landmark event. It provides fast results; it is easy to use and has a low biohazard level that facilitates its implementation in rural settings. Previous modelling studies have already considered it cost-effective in low-and middle-income settings as a replacement test of SM and clinical diagnosis, and as a screening method in HIV-infected patients initiating ART [38, 39] . However, the extent of cost-effectiveness gain to TB programmes depends on current TB diagnostic practices and Xpert â MTB/RIF has been deemed to be too expensive for a point-of-care treatment setting and has been recommended to be installed only at laboratory facilities [40] . MODS was specifically developed and designed to be set up in lowincome countries. Nevertheless, its feasibility in rural areas is of concern and WHO has not recommended its implementation at a district level [41] . Information to date raised the possibility of MODS being better than Xpert â MTB/RIF from a cost-effectiveness perspective as MODS is more sensitive in PLWH and its implementation could be less costly tan Xpert â MTB/ RIF. However, direct cost-effectiveness comparison to date had only been short time oriented and had been performed evaluating the impact on TB incidence in broad regions. Our study provides, to our best knowledge, the first cost-utility comparison of these two diagnostic techniques in a rural high HIV prevalence low-income setting.
Our results reinforce the WHO conditional recommendation of using Xpert â MTB/RIF as a first-line test for every pulmonary TB suspect in rural Sub-Saharan Africa with a long-term utility-based evaluation. The ICER found in our study is within the same range of those found in other studies in other settings, namely South Africa, India and Uganda [38, 42] . Whether Xpert â MTB/RIF is such a huge step forward in TB diagnostics that it should replace the 125-year-old SM as the first TB diagnostic test remains controversial [8] . It has been reported as cost-effective with a very low ICER for many countries with high TB burden and intermediate TB burden [43] [44] [45] . Recently, it has even been deemed cost-effective in different evaluations undertaken in highincome low-TB burden countries, namely the United Kingdom, as an add-on to present care, and in Germany, as a replacement for sputum smear [46, 47] . However, when evaluated in clinical trials, shorter time to TB treatment when using Xpert â MTB/RIF has not translated into lower TB morbidity nor mortality [48, 49] . These results suggest that more than better diagnostic techniques are needed to improve outcomes in TB programmes. In our study, we found a high variability in the PSA, with negative ICER in a substantial number of runs. We believe that this is reflecting that multiple factors influence the final outcomes and not only the sensitivity of the diagnostic techniques. Other interventions along the TB diagnostic and treatment cascade (as improving patients' linkage to care) may be key to improving TB programmes outcomes and should be further analysed. In this setting, the suboptimal treatment outcomes may influence substantially and negatively the effectiveness. Also, the healthcare seeking rate, which was given a wide prior distribution in the PSA as it was considered unknown, could partially explain the high variability.
MODS implementation did not reach the WTP threshold in our analysis and was clearly dominated by Xpert â MTB/RIF. In the one-way sensitivity analysis, only in case of very high TB prevalence or risk of infection, did MODS have an ICER similar to Xpert â MTB/RIF. This finding raises the hypothesis that perhaps in a setting with very high TB prevalence MODS could have its place. Also, the possible added value of DST was not explored as we assumed that there was no MDR-TB. MDR-TB is not very frequent in Mozambique, and thus, the expected impact might be small [50] . Nevertheless, treatment cost of MDR-TB is high and full DST provided by MODS could be of advantage. However, the new Xpert â MTB/RIF Ultra with the XDR cartridge might overshadow this possible added value. Further analyses are needed to evaluate this issue.
Our study has certain limitations. We found a lack of precise information about local TB epidemiology, some parameters of the diagnostic pathway and costs that could generate a high degree of uncertainty. However, we believe that we used the best available estimates, and sensitivity analyses were undertaken to minimise the impact of this uncertainty. Costing was based on a thorough budgeting exercise, but no implementation study was undertaken. Therefore, there could be unforeseen costs that have been unaccounted. However, a PSA with a wide prior distribution of costs was undertaken, not impacting the results.
Choosing the WTP at one time the per capita GNI of Mozambique is certainly standard practice, but it has recently been questioned as there is no evidential basis for it. The main issue is that this threshold is arbitrary and may not reflect societal willingness to pay. Other approaches to establish a WTP have been used as benchmark approaches and league tables but also have limitations. We are not aware of any study exploring the societal willingness to pay in Mozambique, so we chose the per capita GNI despite its limitations. However, to answer the study question, we also present a small league table ordering the ICERs of the different interventions and the results still favour the substitution of SM by Xpert â MTB/RIF (Table 3) . Our results are based on the TB programme of a rural district with high HIV/TB prevalence in Northern Mozambique and are therefore of limited generalisability. Nevertheless, rural African settings, such as Ancuabe district, are very remote and inaccessible and therefore are often not evaluated. So, exploring the implementation of different TB diagnostic techniques in these remote areas is one of the added values of our study.
In summary, replacing SM with Xpert â MTB/RIF for the evaluation of all TB suspects was most likely to be cost-effective in this rural and remote African setting. Our results reinforce the WHO recommendation of Xpert â MTB/RIF being the first diagnostic test in every pulmonary TB suspect and add to a growing body of evidence, suggesting that SM is a technique to replace when possible. 
